Adam Koppel - Net Worth and Insider Trading

Adam Koppel Net Worth

The estimated net worth of Adam Koppel is at least $3.2 Billion dollars as of 2025-04-30. Adam Koppel is the Director, 10% Owner of Cerevel Therapeutics Holdings Inc and owns about 65,683,063 shares of Cerevel Therapeutics Holdings Inc (CERE) stock worth over $3.0 Billion. Adam Koppel is the Director of Dicerna Pharmaceuticals Inc and owns about 3,080,237 shares of Dicerna Pharmaceuticals Inc (DRNA) stock worth over $118 Million. Adam Koppel is also the Director of PTC Therapeutics Inc and owns about 2,333,333 shares of PTC Therapeutics Inc (PTCT) stock worth over $116 Million. Besides these, Adam Koppel also holds Aptinyx Inc (APTX) , Solid Biosciences Inc (SLDB) , Biogen Inc (BIIB) . Details can be seen in Adam Koppel's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Adam Koppel has not made any transactions after 2023-10-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Adam Koppel

Adam Koppel Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Adam Koppel owns 15 companies in total, including Aptinyx Inc (APTX) , Annexon Inc (ANNX) , and Solid Biosciences Inc (SLDB) among others .

Click here to see the complete history of Adam Koppel’s form 4 insider trades.

Insider Ownership Summary of Adam Koppel

Ticker	Company	Transaction Date	Type of Owner
APTX	Aptinyx Inc	2020-01-14	director
ANNX	Annexon Inc	2020-07-23	10 percent owner
SLDB	Solid Biosciences Inc	2018-01-30	director
		2020-12-10	director
		2020-01-30	10 percent owner
		2019-09-12	10 percent owner
		2018-07-19	10 percent owner
		2014-09-17	director
		2017-09-19	10 percent owner
		2017-01-03	director
		2016-06-06	EVP & Strategy and Bus. Dev.
		2020-10-21	director & 10 percent owner
		2020-10-22	director
		2021-07-14	10 percent owner
		2023-10-16	director

Adam Koppel Latest Holdings Summary

Adam Koppel currently owns a total of 6 stocks. Among these stocks, Adam Koppel owns 65,683,063 shares of Cerevel Therapeutics Holdings Inc (CERE) as of October 16, 2023, with a value of $3.0 Billion and a weighting of 92.64%. Adam Koppel owns 3,080,237 shares of Dicerna Pharmaceuticals Inc (DRNA) as of December 10, 2020, with a value of $118 Million and a weighting of 3.69%. Adam Koppel also owns 2,333,333 shares of PTC Therapeutics Inc (PTCT) as of June 25, 2013, with a value of $116 Million and a weighting of 3.62%. The other 3 stocks Aptinyx Inc (APTX) , Solid Biosciences Inc (SLDB) , Biogen Inc (BIIB) have a combined weighting of 0.04% among all his current holdings.

Latest Holdings of Adam Koppel

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
CERE	Cerevel Therapeutics Holdings Inc	2023-10-16	65,683,063	44.96	2,953,110,512
DRNA	Dicerna Pharmaceuticals Inc	2020-12-10	3,080,237	38.22	117,726,658
PTCT	PTC Therapeutics Inc	2013-06-25	2,333,333	49.52	115,546,650
APTX	Aptinyx Inc	2020-01-14	5,558,425	0.10	533,609
SLDB	Solid Biosciences Inc	2018-01-30	132,630	3.05	404,522
BIIB	Biogen Inc	2016-06-06	2,402	120.17	288,648

Holding Weightings of Adam Koppel

Adam Koppel Form 4 Trading Tracker

According to the SEC Form 4 filings, Adam Koppel has made a total of 2 transactions in Cerevel Therapeutics Holdings Inc (CERE) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Cerevel Therapeutics Holdings Inc is the acquisition of 5,480,052 shares on October 16, 2023, which cost Adam Koppel around $125 Million.

According to the SEC Form 4 filings, Adam Koppel has made a total of 1 transactions in Dicerna Pharmaceuticals Inc (DRNA) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Dicerna Pharmaceuticals Inc is the sale of 1,000,000 shares on December 10, 2020, which brought Adam Koppel around $23 Million.

According to the SEC Form 4 filings, Adam Koppel has made a total of 0 transactions in PTC Therapeutics Inc (PTCT) over the past 5 years. The most-recent trade in PTC Therapeutics Inc is the acquisition of 1,250,000 shares on June 25, 2013, which cost Adam Koppel around $19 Million.

More details on Adam Koppel's insider transactions can be found in the Insider Trading History of Adam Koppel table.

Insider Trading History of Adam Koppel

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Adam Koppel Trading Performance

GuruFocus tracks the stock performance after each of Adam Koppel's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Adam Koppel is 23.18%. GuruFocus also compares Adam Koppel's trading performance to market benchmark return within the same time period. The performance of stocks bought by Adam Koppel within 3 months outperforms 4 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Adam Koppel's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Adam Koppel

Average Return

Average return per transaction

Outperforming Transactions

4 out of 5 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	20
Relative Return to S&P 500(%)	17.33

Adam Koppel Ownership Network

Ownership Network List of Adam Koppel

No Data

Ownership Network Relation of Adam Koppel

Adam Koppel Owned Company Details

What does Aptinyx Inc do?

Who are the key executives at Aptinyx Inc?

Adam Koppel is the director of Aptinyx Inc. Other key executives at Aptinyx Inc include director & CEO and President Norbert G Riedel , CFO and CBO Ashish Khanna , and 10 percent owner Bain Capital Life Sciences Investors, Llc .

Aptinyx Inc (APTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aptinyx Inc (APTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aptinyx Inc (APTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aptinyx Inc (APTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aptinyx Inc Insider Transactions

No Available Data

What does Annexon Inc do?

Who are the key executives at Annexon Inc?

Adam Koppel is the 10 percent owner of Annexon Inc. Other key executives at Annexon Inc include EVP & Chief Scientific Officer Dean Richard Artis , EVP & Chief Financial Officer Jennifer Lew , and EVP & Chief Innovation Officer Ted Yednock .

Annexon Inc (ANNX) Insider Trades Summary

Over the past 18 months, Adam Koppel made no insider transaction in Annexon Inc (ANNX). Other recent insider transactions involving Annexon Inc (ANNX) include a net sale of 85,113 shares made by Ted Yednock , a net purchase of 25,600 shares made by William H. Carson , and a net sale of 14,204 shares made by Jennifer Lew .

In summary, during the past 3 months, insiders sold 42,926 shares of Annexon Inc (ANNX) in total and bought 0 shares, with a net sale of 42,926 shares. During the past 18 months, 133,283 shares of Annexon Inc (ANNX) were sold and 375,600 shares were bought by its insiders, resulting in a net purchase of 242,317 shares.

Annexon Inc (ANNX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Annexon Inc Insider Transactions

No Available Data

What does Solid Biosciences Inc do?

Who are the key executives at Solid Biosciences Inc?

Adam Koppel is the director of Solid Biosciences Inc. Other key executives at Solid Biosciences Inc include director & 10 percent owner Perceptive Life Sciences Master Fund Ltd , 10 percent owner Bain Capital Life Sciences Investors, Llc , and Chief Medical Officer Gabriel Brooks .

Solid Biosciences Inc (SLDB) Insider Trades Summary

Over the past 18 months, Adam Koppel made no insider transaction in Solid Biosciences Inc (SLDB). Other recent insider transactions involving Solid Biosciences Inc (SLDB) include a net sale of 4,654 shares made by Ilan Ganot , a net sale of 16,000 shares made by David T Howton , and a net sale of 12,568 shares made by Jessie Hanrahan .

In summary, during the past 3 months, insiders sold 30,824 shares of Solid Biosciences Inc (SLDB) in total and bought 6,254,405 shares, with a net purchase of 6,223,581 shares. During the past 18 months, 86,375 shares of Solid Biosciences Inc (SLDB) were sold and 10,570,378 shares were bought by its insiders, resulting in a net purchase of 10,484,003 shares.

Solid Biosciences Inc (SLDB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Solid Biosciences Inc Insider Transactions

No Available Data

What does Dicerna Pharmaceuticals Inc do?

Who are the key executives at Dicerna Pharmaceuticals Inc?

Adam Koppel is the director of Dicerna Pharmaceuticals Inc. Other key executives at Dicerna Pharmaceuticals Inc include See Remarks Bob D Brown , EVP & Chief Medical Officer Shreeram Aradhye , and director & President and CEO Douglas Fambrough .

Dicerna Pharmaceuticals Inc (DRNA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Dicerna Pharmaceuticals Inc (DRNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Dicerna Pharmaceuticals Inc (DRNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Dicerna Pharmaceuticals Inc (DRNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dicerna Pharmaceuticals Inc Insider Transactions

No Available Data

What does Arcutis Biotherapeutics Inc do?

Who are the key executives at Arcutis Biotherapeutics Inc?

Adam Koppel is the 10 percent owner of Arcutis Biotherapeutics Inc. Other key executives at Arcutis Biotherapeutics Inc include director & President and CEO Todd Franklin Watanabe , See Remarks Patrick Burnett , and SVP and General Counsel Masaru Matsuda .

Arcutis Biotherapeutics Inc (ARQT) Insider Trades Summary

Over the past 18 months, Adam Koppel made no insider transaction in Arcutis Biotherapeutics Inc (ARQT). Other recent insider transactions involving Arcutis Biotherapeutics Inc (ARQT) include a net sale of 281,896 shares made by Patrick Burnett , a net sale of 117,658 shares made by Todd Franklin Watanabe , and a net sale of 100,000 shares made by Howard G. Welgus .

In summary, during the past 3 months, insiders sold 179,853 shares of Arcutis Biotherapeutics Inc (ARQT) in total and bought 0 shares, with a net sale of 179,853 shares. During the past 18 months, 593,204 shares of Arcutis Biotherapeutics Inc (ARQT) were sold and 33,840 shares were bought by its insiders, resulting in a net sale of 559,364 shares.

Arcutis Biotherapeutics Inc (ARQT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arcutis Biotherapeutics Inc Insider Transactions

No Available Data

What does SpringWorks Therapeutics Inc do?

Who are the key executives at SpringWorks Therapeutics Inc?

Adam Koppel is the 10 percent owner of SpringWorks Therapeutics Inc. Other key executives at SpringWorks Therapeutics Inc include director & Chief Executive Officer Saqib Islam , Chief Business Officer Badreddin Edris , and Chief Commercial Officer Bhavesh Ashar .

SpringWorks Therapeutics Inc (SWTX) Insider Trades Summary

Over the past 18 months, Adam Koppel made no insider transaction in SpringWorks Therapeutics Inc (SWTX). Other recent insider transactions involving SpringWorks Therapeutics Inc (SWTX) include a net sale of 284,000 shares made by Saqib Islam , a net sale of 110,000 shares made by Badreddin Edris , and a net sale of 223,000 shares made by Daniel Lynch .

In summary, during the past 3 months, insiders sold 454,540 shares of SpringWorks Therapeutics Inc (SWTX) in total and bought 0 shares, with a net sale of 454,540 shares. During the past 18 months, 715,425 shares of SpringWorks Therapeutics Inc (SWTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 715,425 shares.

SpringWorks Therapeutics Inc (SWTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

SpringWorks Therapeutics Inc Insider Transactions

No Available Data

What does Replimune Group Inc do?

Who are the key executives at Replimune Group Inc?

Adam Koppel is the 10 percent owner of Replimune Group Inc. Other key executives at Replimune Group Inc include Chief Commercial Officer Sushil Patel , Chief Commercial Officer Christopher Sarchi , and Chief Medical Officer Konstantinos Xynos .

Replimune Group Inc (REPL) Insider Trades Summary

Over the past 18 months, Adam Koppel made no insider transaction in Replimune Group Inc (REPL). Other recent insider transactions involving Replimune Group Inc (REPL) include a net sale of 36,807 shares made by Konstantinos Xynos , a net sale of 12,680 shares made by Christopher Sarchi , and a net sale of 30,194 shares made by Sushil Patel .

In summary, during the past 3 months, insiders sold 0 shares of Replimune Group Inc (REPL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 157,924 shares of Replimune Group Inc (REPL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 157,924 shares.

Replimune Group Inc (REPL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Replimune Group Inc Insider Transactions

No Available Data

What does Trevena Inc do?

Who are the key executives at Trevena Inc?

Adam Koppel is the director of Trevena Inc. Other key executives at Trevena Inc include SVP & Chief Medical Officer Mark Demitrack , SVP & Chief Business Officer Robert T Yoder , and director & President & CEO Carrie L. Bourdow .

Trevena Inc (TRVN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Trevena Inc (TRVN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Trevena Inc (TRVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Trevena Inc (TRVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Trevena Inc Insider Transactions

No Available Data

What does Marinus Pharmaceuticals Inc do?

Who are the key executives at Marinus Pharmaceuticals Inc?

Adam Koppel is the 10 percent owner of Marinus Pharmaceuticals Inc. Other key executives at Marinus Pharmaceuticals Inc include Chief Commercial Officer Christina Shafer , CFO Steven Pfanstiel , and Chief Medical Officer Joseph Hulihan .

Marinus Pharmaceuticals Inc (MRNS) Insider Trades Summary

Over the past 18 months, Adam Koppel made no insider transaction in Marinus Pharmaceuticals Inc (MRNS). Other recent insider transactions involving Marinus Pharmaceuticals Inc (MRNS) include a net sale of 6,212 shares made by Scott Braunstein , a net sale of 4,828 shares made by Joseph Hulihan , and a net sale of 4,657 shares made by Steven Pfanstiel .

In summary, during the past 3 months, insiders sold 0 shares of Marinus Pharmaceuticals Inc (MRNS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 32,281 shares of Marinus Pharmaceuticals Inc (MRNS) were sold and 5,933 shares were bought by its insiders, resulting in a net sale of 26,348 shares.

Marinus Pharmaceuticals Inc (MRNS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Marinus Pharmaceuticals Inc Insider Transactions

No Available Data

What does PTC Therapeutics Inc do?

Who are the key executives at PTC Therapeutics Inc?

Adam Koppel is the director of PTC Therapeutics Inc. Other key executives at PTC Therapeutics Inc include Chief Development Officer Matthew B. Klein , Chief Medical Officer Lee Scott Golden , and Chief Business Officer Eric Pauwels .

PTC Therapeutics Inc (PTCT) Insider Trades Summary

Over the past 18 months, Adam Koppel made no insider transaction in PTC Therapeutics Inc (PTCT). Other recent insider transactions involving PTC Therapeutics Inc (PTCT) include a net sale of 45,874 shares made by Matthew B. Klein , a net sale of 197,526 shares made by Mark Elliott Boulding , and a net sale of 22,687 shares made by Eric Pauwels .

In summary, during the past 3 months, insiders sold 134,571 shares of PTC Therapeutics Inc (PTCT) in total and bought 0 shares, with a net sale of 134,571 shares. During the past 18 months, 446,544 shares of PTC Therapeutics Inc (PTCT) were sold and 7,700 shares were bought by its insiders, resulting in a net sale of 438,844 shares.

PTC Therapeutics Inc (PTCT)'s detailed insider trading history can be found in Insider Trading Tracker table.

PTC Therapeutics Inc Insider Transactions

No Available Data

What does Biogen Inc do?

Who are the key executives at Biogen Inc?

Adam Koppel is the EVP & Strategy and Bus. Dev. of Biogen Inc. Other key executives at Biogen Inc include Head of Development Priya Singhal , Head of Research Jane Grogan , and EVP & Human Resources Ginger Gregory .

Biogen Inc (BIIB) Insider Trades Summary

Over the past 18 months, Adam Koppel made no insider transaction in Biogen Inc (BIIB). Other recent insider transactions involving Biogen Inc (BIIB) include a net sale of 2,167 shares made by Priya Singhal , a net sale of 8,760 shares made by Stephen A Sherwin , and a net purchase of 455 shares made by Eric K Rowinsky .

In summary, during the past 3 months, insiders sold 8,760 shares of Biogen Inc (BIIB) in total and bought 0 shares, with a net sale of 8,760 shares. During the past 18 months, 10,927 shares of Biogen Inc (BIIB) were sold and 455 shares were bought by its insiders, resulting in a net sale of 10,472 shares.

Biogen Inc (BIIB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Biogen Inc Insider Transactions

No Available Data

What does BCLS Acquisition Corp do?

Who are the key executives at BCLS Acquisition Corp?

Adam Koppel is the director & 10 percent owner of BCLS Acquisition Corp. Other key executives at BCLS Acquisition Corp include director & 10 percent owner & Chief Executive Officer Jeffrey Lawrence Schwartz , director & 10 percent owner & Chief Financial Officer Hack Andrew A. F. , and 10 percent owner Bcls Acquisition Holdings (gp), Llc .

BCLS Acquisition Corp (BLSA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of BCLS Acquisition Corp (BLSA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of BCLS Acquisition Corp (BLSA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

BCLS Acquisition Corp (BLSA)'s detailed insider trading history can be found in Insider Trading Tracker table.

BCLS Acquisition Corp Insider Transactions

No Available Data

What does Foghorn Therapeutics Inc do?

Who are the key executives at Foghorn Therapeutics Inc?

Adam Koppel is the director of Foghorn Therapeutics Inc. Other key executives at Foghorn Therapeutics Inc include Chief People Officer Carlos Costa , See Remarks Steven F. Bellon , and Chief Strategy/Bus Ops Officer Fanny Cavalie .

Foghorn Therapeutics Inc (FHTX) Insider Trades Summary

Over the past 18 months, Adam Koppel made no insider transaction in Foghorn Therapeutics Inc (FHTX). Other recent insider transactions involving Foghorn Therapeutics Inc (FHTX) include a net sale of 58,859 shares made by Carlos Costa , a net sale of 20,000 shares made by Steven F. Bellon , and a net sale of 11,000 shares made by Fanny Cavalie .

In summary, during the past 3 months, insiders sold 0 shares of Foghorn Therapeutics Inc (FHTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 89,859 shares of Foghorn Therapeutics Inc (FHTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 89,859 shares.

Foghorn Therapeutics Inc (FHTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Foghorn Therapeutics Inc Insider Transactions

No Available Data

What does Rapid Micro Biosystems Inc do?

Who are the key executives at Rapid Micro Biosystems Inc?

Adam Koppel is the 10 percent owner of Rapid Micro Biosystems Inc. Other key executives at Rapid Micro Biosystems Inc include Chief Financial Officer Sean M Wirtjes , director & President and CEO Spignesi Robert G. Jr. , and 10 percent owner Kennedy Lewis Capital Partners Master Fund Ii Lp .

Rapid Micro Biosystems Inc (RPID) Insider Trades Summary

Over the past 18 months, Adam Koppel made no insider transaction in Rapid Micro Biosystems Inc (RPID). Other recent insider transactions involving Rapid Micro Biosystems Inc (RPID) include a net purchase of 40,000 shares made by Melinda Litherland Pei , a net purchase of 65,000 shares made by Richard S Kollender , and a net purchase of 50,000 shares made by Spignesi Robert G. Jr. .

In summary, during the past 3 months, insiders sold 0 shares of Rapid Micro Biosystems Inc (RPID) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Rapid Micro Biosystems Inc (RPID) were sold and 215,000 shares were bought by its insiders, resulting in a net purchase of 215,000 shares.

Rapid Micro Biosystems Inc (RPID)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rapid Micro Biosystems Inc Insider Transactions

No Available Data

What does Cerevel Therapeutics Holdings Inc do?

Who are the key executives at Cerevel Therapeutics Holdings Inc?

Adam Koppel is the director of Cerevel Therapeutics Holdings Inc. Other key executives at Cerevel Therapeutics Holdings Inc include director & See Remarks N Anthony Coles , Chief Scientific Officer John Renger , and Chief Medical Officer Ramiro Sanchez .

Cerevel Therapeutics Holdings Inc (CERE) Insider Trades Summary

Over the past 18 months, Adam Koppel made no insider transaction in Cerevel Therapeutics Holdings Inc (CERE). Other recent insider transactions involving Cerevel Therapeutics Holdings Inc (CERE) include a net sale of 477,506 shares made by N Anthony Coles , a net sale of 37,652 shares made by Ramiro Sanchez , and a net sale of 24,572 shares made by Scott Akamine .

In summary, during the past 3 months, insiders sold 0 shares of Cerevel Therapeutics Holdings Inc (CERE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 614,262 shares of Cerevel Therapeutics Holdings Inc (CERE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 614,262 shares.

Cerevel Therapeutics Holdings Inc (CERE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cerevel Therapeutics Holdings Inc Insider Transactions

No Available Data

Adam Koppel Mailing Address

Above is the net worth, insider trading, and ownership report for Adam Koppel. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Adam Koppel's mailing address is: Boston Ma 02116.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.